Holen Sie sich die Stockscreener-App
390.59
0.59%
-2.5799
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Me - GuruFocus
Gordon Reid's Past Picks: Amgen, Qualcomm & United Rentals - BNN Bloomberg
Amgen’s Phase III DeLLphi-305 study deliverers strong results - The Pharma Letter
Amgen's Imdelltra scores again in small cell lung cancer - pharmaphorum
Amgen stock falls sharply as trial read-through and Tavneos risk unsettle investors - AD HOC NEWS
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - finance.yahoo.com
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension - TIKR.com
Baird Financial Group Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Amgen stock heads into the open after a 10.1% drop - AD HOC NEWS
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Canada
Amgen Tells 4th Circ. No Point In Keeping CareFirst Suit Alive - Law360
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial - WTVB
A Look at Amgen Inc (AMGN) After 10.1% Decline -- GF Value $365. - GuruFocus
AMGN Looks 7.5% Overvalued on GF Value™ After Late-Stage Trial C - GuruFocus
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons - The Motley Fool
Stocks to Watch Recap: Intel, Amgen, Qualcomm, Rigetti - WSJ
Amgen slides 10% amid olpasiran read-through concerns (AMGN:NASDAQ) - Seeking Alpha
Amgen, Novartis, Qualcomn, Corning, Lumentum, and More Stocks That Explain Today’s Market - Barron's
AMGN Looks 8.2% Overvalued on GF Value™ - GuruFocus
Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study - Reuters
Amgen: Why Rivals' Cholesterol Drug Failure Is Bad News For The Pharma (Rating Downgrade) - Seeking Alpha
Amgen Drops 9.0% Amid Sector-Wide Selling - AlphaStreet
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000 - TradingView
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today - Benzinga
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% - finance.yahoo.com
Amgen, Salesforce Share Losses Contribute To Dow's 525-Point Fall - Moomoo
What's Going On With Amgen Stock Tuesday? - Benzinga
Amgen caught in the crossfire of Novartis' failure - marketscreener.com
Amgen (NASDAQ:AMGN) Shares Gap DownHere's Why - MarketBeat
Amgen (NASDAQ:AMGN): What’s Driving the Fresh Market Buzz? - Kalkine Media
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday - finance.yahoo.com
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
Why Amgen Stock Is Down 8.7% And What's Next After Lp(a) Drug Doubts - simplywall.st
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
Amgen Announces Landmark Results From The Phase 3 DeLLphi-305 Study Demonstrating Statistically Significant And Clinically Meaningful Improvement In Overall Survival With IMDELLTRA In Combination With Imfinzi Compared To Durvalumab Alone - marketscreener.com
Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis - TradingKey
Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - Barron's
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $400 - GuruFocus
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly - qz.com
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER - PR Newswire
Amgen (NASDAQ:AMGN) Receives "Neutral" Rating from Cantor Fitzgerald - MarketBeat
Is AMGN Overvalued? DCF Says Worth $296 - GuruFocus
BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts - Investing.com Canada
Amgen Shares Fall as Investors Assess Novartis Lp(a) Trial Result and BMO Downgrade - finance.yahoo.com
Novartis Faces Setback with Pelacarsen Clinical Trial, Impacting Competitors - GuruFocus
Why Amgen Stock Is Dropping After Swiss Rival’s Trial Setback - Barron's
Why is Amgen stock sliding today? By Investing.com - Investing.com Canada
BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450 - marketscreener.com
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases Shares of 80,985 Amgen Inc. $AMGN - marketbeat.com
Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy… - marketscreener.com
Understanding Momentum Shifts in (AMGN) - Stock Traders Daily
Ameritas Advisory Services LLC Has $5.11 Million Stake in Amgen Inc. $AMGN - MarketBeat
Rep. David Taylor Sells Off Amgen Inc. (NASDAQ:AMGN) Stock - MarketBeat
Amgen stock heads into the open after a 1.55% pullback - AD HOC NEWS
Amgen Seeks Korean Partners in AI Drug Discovery, Obesity - Seoul Economic Daily
Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar - TradingView
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal - finance.yahoo.com
Amgen stock holds near 52-week high as major investors adjust positions - AD HOC NEWS
HighTower Advisors LLC Sells 4,063 Shares of Amgen Inc. $AMGN - MarketBeat
Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks… - marketscreener.com
1.07%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):